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ABSTRACT
Constitutive and induced protein SUMOylation
is involved in the regulation of a variety of cellular
processes, such as regulation of gene expression
and protein transport, and proceeds mainly in
the nucleus of the cell. So far, several hundred
SUMOylation targets have been identified, but
presumably they represent only a part of the total
of proteins which are regulated by SUMOylation.
Here, we used the Ubc9 fusion-dependent
SUMOylation system (UFDS) to screen for constitu-
tive and induced SUMOylation of 46 randomly
chosen proteins with proven or potential nuclear
localization. Fourteen new UFDS-substrate proteins
were identified of which eight could be demon-
strated to be SUMOylated in a UFDS-independent
manner in vivo. Of these, three were constitutively
SUMOylated (FOS, CRSP9 and CDC37) while
the remaining five substrates (CSNK2B, TAF10,
HSF2BP, PSMC3 and DRG1) showed a stimulation-
dependent SUMOylation induced by the MAP3
kinase MEKK1. Hence, UFDS is appropriate for
the identification and characterization of consti-
tutive and, more importantly, induced protein
SUMOylation in vivo.
INTRODUCTION
SUMOylation is a protein conjugation process which leads
to covalent modiﬁcation of many proteins involved in
transcriptional regulation, protein transport, chromosome
segregation and signal transduction in a constitutive or
even stimulation-dependent manner (1). The three mam-
malian SUMO isoforms (SUMO1–3) are expressed as
precursor proteins and subsequently cleaved at their
C-terminus by one of ﬁve SUMO-speciﬁc proteases
(SENP1–3, SENP5 and SENP6) (1). A complex consisting
of SAE1 and SAE2 (E1) (2–5) activates the maturated
SUMO and transfers it to the conjugating enzyme Ubc9
(E2) (6,7). Its interaction with a substrate protein then
induces the transfer of the SUMO moiety onto the
substrate protein and the formation of the isopeptide
bond (8). Most SUMOylation processes also seem to be
assisted by SUMO ligases, which beside their diﬀerent
functions act as adapters that bind the conjugating enzyme
Ubc9 and the substrate protein. Such SUMO ligases are
the members of the PIAS (protein inhibitor of activated
STAT; PIAS1, PIAS3, PIASxa, PIASxb and PIASy)
protein family (9), the Polycomb group protein Pc2 (10)
and the RanBP2 (11,12), a protein of the nuclear pore. The
amount of SUMOylated proteins in the cell is further
regulated by the ﬁve SUMO-speciﬁc proteases, which
display SUMO deconjugating activity as well (1). The
number of identiﬁed SUMOylation substrates is steadily
increasing especially through proteomic studies (13–17)
but only for about 60 SUMOylation substrates the func-
tion of the SUMOylation is characterized in detail (18).
Recently, a Ubc9 fusion-directed SUMOylation
(UFDS) system was developed that strongly increases
the degree of SUMOylation of a speciﬁc substrate protein
fused to Ubc9 in vivo. UFDS is eﬃcient, selective for the
in vivo SUMOylation sites and independent of SUMO
ligases (19). This method should be well suited to screen
for new SUMOylation substrates and, therefore, we
applied UFDS for the identiﬁcation of new in vivo
SUMOylation substrates leading to 14 potential new
substrate candidates. Veriﬁcation of eight of these new
substrates by UFDS independent methods revealed that
the UFDS system is capable of identifying constitutive
and induced SUMOylations.
MATERIALS AND METHODS
Plasmids
The destination vector (pCU-B) for the fusion of open
reading frames to the N-terminus of Ubc9 was made by
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(Invitrogen) into the ﬁlled-in EcoRI site of the pcDNA3-
MCS-Ubc9. The destination vector for the fusion of open
reading frames to the C-terminus of Ubc9 was made by
amplifying the Ubc9 cDNA using the primers se-50-CCTC
GGATCCGTTATGTCGGGGATCGCCCTCAG-30 and
ase-50-CCTCGAATTCTGAGGGGGCAAACTTCTTC
G-30 and cloning the PCR product into the BamHI/EcoRI
sites of pcDNA3. Then, the Gateway-RfC.1 recombina-
tion cassette (Invitrogen) was cloned in the EcoRV site of
the pcDNA3-Ubc9-MCS to obtain the destination vector
pNU-C.1. The Ubc9-ORF/ORF-Ubc9 fusion protein
expression vectors were obtained by recombination of
the above described destination vectors with the ORF
harboring entry plasmids (from the RZPD Deutsches
Ressourcenzentrum fu ¨ r Genomforschung) with the
Gateway recombination system (Invitrogen).
Cells and materials
HEK293 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium with high glucose, complemented with
10% fetal calf serum, 2mM L-glutamine, 100 U/ml
penicillin and 100mg/ml streptomycin. Antibodies against
the following proteins or peptides were used: Ubc9
(H81, Santa Cruz) and GFP (B-2, Santa Cruz).
Horseradish peroxidase-coupled secondary antibodies
were from Santa Cruz.
Transfection, cell lysis andwestern blotting
Transfection of 50–80% conﬂuent HEK293 cells was
performed in 12-well plates using the Polyfect transfection
reagent (Qiagen) according to the instructions of the
supplier. Transfectants were grown for 24–48h, then lysed
in 150ml gel loading buﬀer (80mM Tris, pH 6.8, 2% SDS,
5% ß-ME, 0.01% bromphenol blue) and incubated for
10min at 958C. For western blot analysis the proteins
were separated by SDS-PAGE, blotted on a PVDF
membrane and developed with a speciﬁc primary anti-
body, an HRP conjugated secondary antibody, the ECL+
(Amersham) and the LAS-3000 imaging system (Fuji).
RESULTS
Identification of SUMOylation target proteins by UFDS
The analysis of protein functions necessitates the identi-
ﬁcation and characterization of post-translational mod-
iﬁcations that are involved in their regulation. Since
SUMOylation of most proteins is hardly detectable
in vivo, we used UFDS to analyze 46 potential nuclear
proteins (Table 1) for their SUMOylation. For an eﬃcient
generation of the expression plasmids for Ubc9 fusion
proteins, we constructed Ubc9 fusion destination vectors
that allowed the fusion of protein coding sequences to
Ubc9 using the ‘Gateway’ cloning-by-recombination
system (Invitrogen). We fused the coding sequences
of the proteins (Table 1) to the N-terminus or the
C-Terminus of Ubc9 (Figure 1A and B), to determine if
Ubc9 can SUMOylate the fused protein in both structural
arrangements. All Ubc9 fusion protein expression vectors
were transfected alone or together with an EGFP-SUMO1
expression vector into HEK293 cells. Proteins of the
transfectants were analyzed by immunoblotting using a
Ubc9 antibody. Of the 46 fusion proteins analyzed,
37 were found to be expressed to diﬀerent degrees, while
9 fusion proteins could not be detected. Of the expressed
fusion proteins, 14 were strongly and 23 were not or only
weakly SUMOylated (c.f. Figure 1C and Table 1). Nine
of the strongly SUMOylated proteins were fusions to the
C-terminus, while the ﬁve others were fusions to the
N-terminus of Ubc9. This demonstrates that Ubc9 is able
to SUMOylate the fused protein in both structural
arrangements. Most of the strongly SUMOylated proteins
we identiﬁed are involved in transcription (CIAO1,
CRSP9, EDF1, FOS, HMGN2, HSF2BP, PC4, TAF10
and ZNRD1). The others are proteins involved in
signal transduction by phosphorylation, such as the
Casein kinase 2, beta polypeptide CSNK2B, the
Ribosomal protein S6 kinase polypeptide 6 (RPS6KA6)
and the p50CDC37, an Hsp90 chaperone protein kinase-
targeting subunit. Furthermore, the proteasome 26S
subunit 6A (PSMC3) and the developmentally regulated
GTP binding protein 1 (DRG1) were identiﬁed.
UFDS-independent verification of SUMOylation
of targetproteins
To verify the newly identiﬁed SUMOylation substrates,
we analyzed their SUMOylation without the Ubc9 fusion.
Because of the unavailability of suitable antibodies for
most of the proteins, the SUMOylation was analyzed
using GST-tagged proteins which can be pulled down
with glutathion-S Sepharose and then be detected with a
GST-antibody. Since SUMOylation of many proteins can
hardly be detected without the presence of a speciﬁc
SUMO ligase, we analyzed the potential SUMOylation
target proteins also in the presence of the known SUMO
ligases PC2, PIAS1/3/xß/g and RanBPi which were
ectopically co-expressed. As a further control, SENP2,
one of the SUMO deconjugating enzymes, was coex-
pressed to demonstrate SUMOylation by its disappear-
ance under these conditions. In vivo-SUMOylation was
ﬁrst tested for the known SUMOylation substrate p53
(21,22) and could be detected when coexpressed with
EGFP-SUMO1 (Figure 2A). When SENP2 is coexpressed
p53 SUMOylation is clearly diminished (Figure 2A).
SUMOylation of p53 is enhanced by the SUMO ligase
PIAS1 (23) and most strongly by PIASg (24) (Figure 2B).
Unexpectedly, in our hands PIASx/ß (25) did not enhance
p53 SUMOylation (Figure 2B). But we found out that
PC2 can enhance the p53 SUMOylation. Of the potential
SUMOylation targets we could verify that FOS
(Figure 3A) is SUMOylated when coexpressed with
EGFP-SUMO1 and de-SUMOylated in the presence of
SENP2. Furthermore its SUMOylation is enhanced by
a coexpression of the SUMO ligases PIAS1 and PIASg.
CRSP9 (Figure 3B) and CDC37 (Figure 3C) are also
SUMOylated when coexpressed with EGFP-SUMO1 and
de-SUMOylated in the presence of SENP2, but there
was no inﬂuence on their SUMOylation by coexpression
of SUMO ligases (data not shown). For the remaining
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SUMOylation when coexpressed with EGFP-SUMO1
and Ubc9 (data not shown). Furthermore, none of the
SUMO ligases PC2, PIAS1/3/xß/g and RanBPi induced
the SUMOylation of these proteins (data not shown),
indicating the involvement of other speciﬁc SUMO ligases
for these targets.
Verification ofinducible SUMOylation
In view of the fact that proteomic studies have identiﬁed
many stimulation-dependent SUMOylations of substrate
proteins (20,26–28) and that phosphorylation-dependent
SUMOylation sites have been recently described (29),
we wondered whether UFDS had identiﬁed stimulation-
dependent SUMOylations. To analyze a stimulation-
dependent SUMOylation independent of UFDS, we
coexpressed the candidate proteins with a constitutively
active MEKK1 (MEKK1ca) (30). The constitutive
SUMOylations of FOS (data not shown) and CRSP9
(Figure 3B) were not enhanced by the MEKK1ca
coexpression, whereas the SUMOylation of CDC37 by
EGFP-SUMO1 was enhanced by coexpressed MEKK1ca
and was strongest when both MEKK1ca and Ubc9 were
present (Figure 3C). For ﬁve other SUMOylation
substrates, CSNK2B (Figure 4A), TAF10 (Figure 4B),
Table 1. Proteins analyzed for SUMOylation by UFDS
Gene Protein Ubc9 SUMOyl
ARAF1 A-Raf proto-oncogene serine/threonine-protein kinase N –
ATF3 Cyclic AMP-dependent transcription factor ATF-3 C Weak
BACH1 Transcription regulator protein BACH1 C –
BHLHB2 Basic helix-loop-helix domain containing, class B, 2 N No
CDC37 CDC37 cell division cycle 37 homolog (S cerevisiae) N Strong/veriﬁed
CDK4 Cyclin-dependent kinase 4 C Weak
CDK5 Cyclin-dependent kinase 5 N Weak
CDKN2D Cyclin-dependent kinase inhibitor 2D (p19) C Weak
CDKN3 Cyclin-dependent kinase inhibitor 3 C Weak
CIAO1 WD40 protein Ciao1 N Yes
CINP Cyclin-dependent kinase 2-interacting protein N Weak
CKS2 CDC28 protein kinase regulatory subunit 2 C No
CRSP9 Cofactor for Sp1 transcriptional activation subunit 9 C Yes/veriﬁed
CSK C-src tyrosine kinase C –
CSNK2B Casein kinase 2, beta polypeptide C Strong/double/veriﬁed
DRG1 Developmentally regulated GTP binding protein 1 C Yes/veriﬁed
DSCR1 Down syndrome critical region gene 1 C No
EDF1 Endothelial diﬀerentiation-related factor 1 C Yes
ELL3 Elongation factor RNA polymerase II-like 3 N No
FOS Proto-oncogene protein c-fos C Strong/veriﬁed
HES1 Hairy and enhancer of split 1, (Drosophila) C No
HMGN2 High-mobility group nucleosomal binding domain 2 N Strong
HNF4G Hepatocyte nuclear factor 4, gamma C –
HSF2BP Heat shock transcription factor 2 binding protein N Strong/double/veriﬁed
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 C –
MAPK13 Mitogen-activated protein kinase 13 C Weak
MYF6 Myogenic factor 6 (herculin) C No
NEK6 NIMA (never in mitosis gene a)-related kinase 6 N Weak
NFE2 Nuclear factor (erythroid-derived 2), 45kDa C –
NFIL3 Nuclear factor, interleukin 3 regulated C –
PC4 Activated RNA polymerase II transcription cofactor 4 N Yes
POLR2C Polymerase (RNA) II (DNA directed) polypeptide C N Weak
PSMC3 Proteasome 26S subunit ATPase 3 N Strong/veriﬁed
PTTG1 Pituitary tumor-transforming 1 C No
RARA Retinoic acid receptor, alpha N No
RFXANK DNA-binding protein RFXANK C No
RPL7 Ribosomal protein L7 N No
RPS6KA6 Ribosomal protein S6 kinase, 90kDa, polypeptide 6 N Strong
STK16 Serine/threonine kinase 16 C No
STK17B Serine/threonine kinase 17b (apoptosis-inducing) C –
TAF10 Transcription initiation factor TFIID subunit 10 N Strong/veriﬁed
TBP TATA box binding protein N Weak
TCF21 Transcription factor 21 C Weak
VDRIP Vitamin D receptor interacting protein C No
ZNF287 Zinc ﬁnger protein 287 N –
ZNRD1 Zinc ribbon domain containing, 1 N Strong/double
The coding sequences of the listed genes were fused with the N-terminus (N) or C-terminus (C) to Ubc9.
SUMOyl=estimation of the SUMOylation by coexpressed EGFP-SUMO1, double indicates a clear double SUMOylation of the protein, veriﬁed
indicates that SUMOylation was also shown without the Ubc9 fusion, - indicates that the fusion protein was not expressed. Examples for Western
blots used for the estimations are shown in Figure 1C.
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(Figure 4E) we detected SUMOylation only when the
various MAP-kinase cascades were activated by coexpres-
sion of MEKK1ca. Thus, UFDS had identiﬁed
both target proteins for constitutive and induced
SUMOylation. For the six remaining new SUMOylation
substrate candidates, we could so far not unequivocally
demonstrate SUMOylation in the absence of a fusion to
Figure 1. Identiﬁcation of new SUMOylation substrates using UFDS. The fusion of Ubc9 to the C-terminus (A) or the N-terminus (B) of a substrate
protein induces the E3-ligase independent SUMOylation of the substrate protein. The expression plasmids for the Ubc9 (U) fusion proteins were
expressed alone or together with EGFP-SUMO1 (E-S1) in HEK293 cells. After 24–48h protein extracts of the transfectants were analyzed by
immunoblotting using an Ubc9 antibody. Examples for strong mono-SUMOylated (HMGN2, TAF10, CDC37 and FOS), strongly di-SUMOylated
(HSF2BP and CSNK2B and ZNRD1), weakly (CDK4) and non-SUMOylated (ELLE3) Ubc9 fusion proteins are shown (C, c.f. Table 1). The bands
for the Ubc9 fusion proteins are marked with P, the EGFP-SUMO1 conjugated Ubc9-fusion proteins with E-P Bands for double EGFP-SUMO1
conjugated Ubc9-fusion proteins are marked with 2E-P, Ubc9-fusion proteins modiﬁed at alternative SUMOylation sites are marked by black
arrows. Bands representing Ubc9-fusion proteins modiﬁed by endogenous SUMO (CIAO1, CRSP9 and FOS) are marked with black asterisks.
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the speciﬁc SUMO ligases or the adequate stimulation in
HEK 293 cells or by artiﬁcial SUMOylation in the Ubc9
fusion proteins. In spite of the large number of new
SUMOylation substrates that were recently identiﬁed in
proteomic studies, only one of the proteins identiﬁed
in this study (FOS) was in parallel recognized as
SUMOylation substrate (20). This clearly makes UFDS
a powerful complementary approach for identifying in
particular stimulation-dependent protein SUMOylation.
DISCUSSION
Although hundreds of potential SUMOylation substrates
have been described recently (1), many proteins were
probably not accessible to this kind of analysis due to low
expression rates or low amount of SUMOylation, which
may result from a lack of expression of speciﬁc SUMO
ligases or of an adequate stimulus. By using UFDS, out of
37 expressed proteins 14 were identiﬁed as SUMOylation
substrates. Eight of these 14 potential SUMOylation
substrates were also SUMOylated in vivo without
fusion of Ubc9. While three of these are SUMOylated
when coexpressed with EGFP-SUMO1 and one exhibited
enhanced SUMOylation when coexpressed with known
SUMO ligases, ﬁve proteins were only SUMOylated when
constitutively activated MEKK1 was coexpressed.
Therefore, constitutively active MEKK1 mimics various
extracellular signal-dependent stimulations of the cell
in parallel and serves as an ideal tool to analyze
signal-regulated SUMOylation for candidate substrates.
However, due to the broad eﬀects of MEKK1ca, no
information about the speciﬁc pathway involved in vivo
can be obtained. Further work using speciﬁc stimuli and
inhibitors of these pathways is needed to understand this
signaling in detail.
The SUMOylation of many proteins is enhanced by
diﬀerent stress stimuli-like heat shock, ethanol, MG132,
serum starvation (26–28) or serum stimulation (20).
Recently, phosphorylation-dependent SUMOylation has
been described where phosphorylation(s) C-terminal to
the SUMOylation site are necessary (29) permitting
signal-regulated SUMOylation. On the other hand, for
the protein STAT1 we have recently shown that
SUMOylation inhibits phosphorylation of a site in the
vicinity of the SUMOylation (19). These ﬁndings demon-
strate a full regulatory cross talk between phosphorylation
and SUMOylation. Here, UFDS identiﬁed SUMOylation
of substrate proteins in non-stimulated cells, whereas these
substrates normally need a special stimulation to become
SUMOylated. Therefore, UFDS can not only be used to
identify constitutive SUMOylation, but also to identify
the induced SUMOylation of proteins which are modiﬁed
in vivo only in the presence of a speciﬁc, often unidentiﬁed
SUMO ligase after a speciﬁc stimulation which may
also alter subcellular localization or activity of this
ligase. Furthermore, these results indicate that UFDS
has the potency to study the function of stimulation-
dependent SUMOylation without any stimulation of the
cell, allowing the characterization of the function of one
speciﬁc SUMOylated protein avoiding interference by
parallel stimulation of other proteins.
The characteristics outlined above make UFDS
eligible for the identiﬁcation and analysis of unknown
SUMOylation-dependent processes. This is demonstrated
by the identiﬁcation of 14 potential SUMOylation
substrates of which only one (FOS) was described as
substrate in parallel (20). The ﬁnding that UFDS is in vivo
independent of both SUMO ligases (19) and speciﬁc
stimuli favors that in case of the remaining six non-veriﬁed
SUMOylation substrates expression of the speciﬁc SUMO
ligase or a speciﬁc stimulation was not reached in HEK
293 cells. Of course, we can also not exclude that those
were artiﬁcially SUMOylated by UFDS.
Interestingly, the majority of the 14 candidate proteins
also represents interaction partners of other described
SUMOylation substrates. CDC37 binds to the androgen
receptor (32), Ciao1 is a binding partner of the Wilms
Tumor suppressor protein WT1 (33), the Endothelial
diﬀerentiation-related factor 1 (EDF1) binds to c-Jun (34)
and Fos (20) and FOS binds to c-Jun as well(20). HSF2BP
binds to the Heat shock transcription factor 2 (HSF2) (35)
and PC4 interacts with p53 (36). TAF10 which we found
to be strongly SUMOylated, is part of the TFIID complex
that comprises the TATA box binding protein (TBP) and
13 TBP-associated factors (TAFs). Two proteins of this
complex, TAF5 and TAF12, have also been reported
to become SUMOylated (37). These data let us assume
that the organization of several multiprotein complexes
is assisted by the SUMOylation of more than one
SUMOylatable proteins.
Figure 2. p53 SUMOylation by Ubc9, SUMO-deconjugating enzyme
(A) and SUMO ligases (B). (A and B) p53 was expressed alone or
together with EGFP-SUMO1 and the indicated proteins in HEK293
cells. After 24h, protein extracts of the transfectants were analyzed by
immunoblotting using a p53 antibody (WB:p53). p53 and the p53
conjugated with endogenous SUMO (S) or with one EGFP-SUMO1
(E-S1) are indicated by black arrow heads. An unspeciﬁc band in
A and B is marked by white arrows.
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others were strongly reduced in their expression by the
coexpression of EGFP-SUMO1. Until now, most reports
on SUMO conclude that SUMOylation is not involved in
proteasomal protein degradation. We have not yet proved
if some of the proteins we investigated are destabilized
upon their Ubc9 fusion dependent SUMOylation, but
UFDS should be an excellent tool for such investigations
at least for proteins which are stated to be destabilized
by SUMOylation (38).
Figure 3. Constitutive SUMOylation of newly identiﬁed substrate proteins without Ubc9 fusion. The expression plasmids for the GST fusion
proteins G-FOS (A), G-CRSP9 (B), G-CDC37 (C) were transfected alone or together with expression plasmids for the indicated proteins in HEK293
cells. After 24h, protein cell lysates were analyzed by immunoblotting using a GST antibody (WB: GST). The fusion proteins conjugated with
endogenous SUMO (S) or with EGFP-SUMO1 (E-S1) are indicated by black arrow heads (A–C). For GST pull downs (pd) 24h after transfection,
the GST fusion proteins from the extracts of transfectants were puriﬁed on glutathione sepharose and analyzed in a western blot with a SUMO1
antibody (WB:SUMO1). Afterwards, the membranes were stripped and the fusion proteins were detected by western blot with a GST antibody
(WB:GST). Additionally, the whole cell lysates (WCL) of the pull downs were analyzed for EGFP-SUMO1 expression by immunoblotting using
a SUMO1 antibody (WB:SUMO1). The EGFP-SUMO1 protein is indicated by a black arrow head, the EGFP-SUMO1 conjugated proteins
(E-S1-protein) are indicated by a black line. An unspeciﬁc band in B is indicated by a white arrow.
e109 Nucleic Acids Research, 2007, Vol. 35, No. 17 PAGE6 OF 8Summarizing our data, it is evident that UFDS could be
a valuable method for the identiﬁcation of constitutive
and stimulated SUMOylation and for the functional
analysis of these kinds of protein SUMOylation leading
to new insights on how SUMOylation regulates protein
function.
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